N@N

Andrew Fein Reiterated (ACAD) at Strong Buy and Held Target at $28 on, Jun 14th, 2023

Andrew Fein of HC Wainwright & Co., Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy and Held Target at $28 on, Jun 14th, 2023.

Andrew has made no other calls on ACAD in the last 4 months.

There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 6 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $26 on, Monday, May 22nd, 2023
• Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $22 on, Tuesday, May 9th, 2023
• Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Tuesday, March 14th, 2023
• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
• Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023

These are the ratings of the 4 analyists that currently disagree with Andrew

---

• Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $27 on, Tuesday, May 9th, 2023
• Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $33 on, Tuesday, May 9th, 2023
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
• Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023

Contributing Sources

---